As of 2025-09-18, the Relative Valuation of Eiger BioPharmaceuticals Inc (EIGR) is (2,908.78) USD. This relative valuation is based on P/E multiples. With the latest stock price at 8.50 USD, the upside of Eiger BioPharmaceuticals Inc based on Relative Valuation is -34320.9%.
The range of the Relative Valuation is (2,335.43) - (3,272.12) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 11.1x - 15.6x | 13.9x |
| Forward P/E multiples | 11.0x - 17.0x | 13.8x |
| Fair Price | (2,335.43) - (3,272.12) | (2,908.78) |
| Upside | -27575.6% - -38595.5% | -34320.9% |
| Date | P/E |